0KCC Stock Overview
A precision diagnostics company, focuses on development and commercialization of proprietary tests in the United States and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
OncoCyte Corporation Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$2.11 |
| 52 Week High | US$4.98 |
| 52 Week Low | US$2.11 |
| Beta | 1 |
| 11 Month Change | -31.88% |
| 3 Month Change | n/a |
| 1 Year Change | -41.93% |
| 33 Year Change | -95.29% |
| 5 Year Change | n/a |
| Change since IPO | -97.40% |
Recent News & Updates
Recent updates
Shareholder Returns
| 0KCC | GB Biotechs | GB Market | |
|---|---|---|---|
| 7D | -25.8% | 2.5% | 2.2% |
| 1Y | -41.9% | -15.4% | 9.0% |
Return vs Industry: 0KCC underperformed the UK Biotechs industry which returned -15.4% over the past year.
Return vs Market: 0KCC underperformed the UK Market which returned 9% over the past year.
Price Volatility
| 0KCC volatility | |
|---|---|
| 0KCC Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 7.9% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in GB Market | 10.3% |
| 10% least volatile stocks in GB Market | 2.6% |
Stable Share Price: 0KCC's share price has been volatile over the past 3 months compared to the UK market.
Volatility Over Time: Insufficient data to determine 0KCC's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2009 | 45 | Josh Riggs | www.oncocyte.com |
OncoCyte Corporation, a precision diagnostics company, focuses on development and commercialization of proprietary tests in the United States and internationally. The company is developing DetermaIO, a gene expression test that assesses the tumor microenvironment to predict response to immunotherapies; DetermaCNI, a blood-based monitoring tool for monitoring therapeutic efficacy in cancer patients; and VitaGraft, a blood-based solid organ transplantation monitoring test. It also provides testing services for biomarker discovery, assay design and development, clinical trial support, and various biomarker tests.
OncoCyte Corporation Fundamentals Summary
| 0KCC fundamental statistics | |
|---|---|
| Market cap | US$40.99m |
| Earnings (TTM) | -US$43.61m |
| Revenue (TTM) | US$709.00k |
57.8x
P/S Ratio-0.9x
P/E RatioIs 0KCC overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 0KCC income statement (TTM) | |
|---|---|
| Revenue | US$709.00k |
| Cost of Revenue | US$593.00k |
| Gross Profit | US$116.00k |
| Other Expenses | US$43.73m |
| Earnings | -US$43.61m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -2.59 |
| Gross Margin | 16.36% |
| Net Profit Margin | -6,150.92% |
| Debt/Equity Ratio | 0% |
How did 0KCC perform over the long term?
See historical performance and comparison